The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
๐๐๐ฅ๐ฎ๐๐ญ๐ข๐จ๐ง: ๐ฆ๐๐ข๐ง๐ญ๐๐ข๐ง๐๐ ๐๐ญ ยฃ๐๐.๐๐ฆ ๐จ๐ซ ๐.๐๐ฉ
Key highlights included the initiation and subsequent positive safety data from @OxCanTech first Phase I clinical trial and a foray into oncology
https://www.edisongroup.com/research/early-signs-of-revival-in-clinical-activity/33216/
Hi chrishutch, totally agreed at this ridiculous price an incredible opportunity to buy at sub 0.005p Given the poor fund rise by the BOD no doubt they will be filling their boots.
Expect the usual positive RNS to land shortly after the raise and should easily bounce back to near 1p. Not good for existing holders like me but I have also taken the opportunity in average down below 0.0048ish making my long term hold here better average.
Amazed how many people canโt see the value in the current price. This is not a keep the lights on moment, this was clever and backed by strength.
I firmly believe we will see a bag or two in the coming months
Currently.
Time to buy in, average down, or take advantage. This is going to be worth more very soon.
Nevertheless its a poor funding at just 0.5, Given the directors are participating it's obvious their personal gain at receiving CLN's or shares for their investment at this level shows little appreciation for existing share holders.
They should have never agreed a 30% discount if they were confident in their products.
Losing confidence
That's not the point.
Finance is out of way, that a good thing.
It's a lot cheaper to do trails in Australia than corrupt UK.
As soon as Hemo rocket, I'm putting my profits in here.
Well done management...
It was also good to see the Board showing a further commitment of personal funds, as well as the caveat that the funds must be used specifically against research in Australia. Clarissa clearly said in recent interviews that Australia was at the forefront of CBD and THC research, plus by taking products to Aus, means the company opens themselves up to a new population of investors. It wouldnโt surprise me if applications to further stock exchanges were made in the regions where research is being performed so well done those who got in super cheap to the party.
Its actually a really big sign of confidence that a multi billion dollar global company such as Cantheon Capital, who only invests in biotech firms with short term catalysts, is investing in OCTP
Read the RNS...
...or listen to the CEO
this facility is more for headroom. An ICON facility. Saves OCTP issuing an expensive prospectus (Maybe ยฃ200-300k)
https://total-market-solutions.com/2024/01/oxford-cannabinoid-technologies-holdings-plc-jan-2024/
Looks like the bottom is in
I cannot be sure about this but I think that last night my neighbour was trying to unlock the therapeutic potential of cannabinoids. ๐คฏ
Nice interview. Become a bit of a no brainer around 0.5s
โThis Cornerstone signals a powerful endorsement of the progress @OxCanTech is makingโ
This Cornerstone signals a powerful endorsement of the progress Oxford Cannabinoid Technologies is making
โโฆOur mission is to unlock the therapeutic potential of cannabinoids and we are some way down that pathโฆโ
Whole article plus interview : https://total-market-solutions.com/2024/01/oxford-cannabinoid-technologies-holdings-plc-jan-2024/
Interview Only : https://youtu.be/hFZGXkKnM_g
Will most likely go beneath placing price before it bounces
I also started buying back in and will continue to do so
.58 is just getting absolutely battered. Very few sells. MMs will need to move this up over the coming hours/days. .80 would start to look like fair value with the fundraise/tax rebate/pipeline.
Small top-up coming from me
Agree, it raise money and have some tax credit for them to go ahead with trial so, it is bottom now...any add will get multiply once trial approve
Dropped from 1.6p back to 0.5p all time lows
The tax credits are huge given their Mcap. The placing is quite small and ultimatley there are some huge catalysts ahead with the clinical trials program
I suspect it will have a very nice run from this area and will get chased at somepoint soon
0.5p fundraise, but not a massive amount of dilution... The R+D tax credit almost pays for the dilution!
0.55 is far far too cheap and will not last long
Apart from the capitol reorganisation.
They have achevie more here than Sareum has in its life time.
I will definitely buy more here, in the next couple of months.
We have some decent results with fantastic progress.
ยฃ1.275m in tax credits whiuch is a huge bonus
And they have raised money at 0.5p which at least should mark the bottom at all time lows ahead of commencement of clinical trials
Results & presentation tomorrow
Alot of trades today, something up.
It's about time we got some news, been awfully quiet here ๐